[e-drug] RxISK Petition for Access to Clinical Trial Data

e-drug
1

E-DRUG: RxISK Petition for Access to Clinical Trial Data
-------------------------------------------------------------------------------
[Humira (TM) is adalimumab and has been used to treat rheumatoid arthritis and some other inflammatory conditions. It has a significant side-effect profile. BS}

Dear e-drug friends

The pharmaceutical company AbbVie, makers of Humira have taken legal action to block the European Medicines' Agency's policy of open access to clinical trial data.

Essentially AbbVie are asking the Courts to grant their Corporation the
privacy rights of an individual - a very powerful wealthy individual. If
this legal action succeeds Adverse Event data will be hidden for ever.

We want you and anyone you know to sign a petition calling on AbbVie to
drop their legal action against the EMA. The petition is here
http://chn.ge/13clTyF

or in Brazilian, Spanish, French, Han,Hindi and soon Urdu and Arabic on
Rxisk here
http://wp.me/p2FaK9-T8

This petition is as much for those prescribed drugs as for those
prescribing them - so we are hoping to spread word about it generally.

We are also trying to get every country in the world to sign. We have 72 of
the 187 countries signed up but would love to have all. Anything you can
do to find us signatures from South East Asia to Central America would be
great.

David
--
David Healy
Professor of Psychiatry
Hergest Unit
Bangor Wales LL57 2PW
United Kingdom
T 44-1248-384453
C 447771897792
E david.healy54@googlemail.com

2

E-DRUG: RxISK Petition for Access to Clinical Trial Data (3)
----------------------------------------------------------------------------------

Sorry for the extreme delay in responding. Dr Bonface Fundafunda asked how
this action might impact on his usual sources of information - WHO, NICE
etc.

The answer may be of general interest - as things stand now WHO and NICE
for instance do not have access to Clinical Trial Data and under the
proposals being put forward by AbbVie and other companies there will be
even less access.

This seems very closely tied to the current round of Trade Talks and is an
agenda being pushed very firmly by Pharma.

The issue is not a European one in that exactly the same arguments are
being deployed by Pharma in the current round of Trade Talks, in the
European Courts and in close to all presentations being made by all the
Branded companies on this and related issues.

David

David Healy
Professor of Psychiatry
Hergest Unit
Bangor Wales LL57 2PW
United Kingdom
T 44-1248-384453
C 447771897792
E david.healy54@googlemail.com
E David.Healy@rxisk.org